# A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

> **NCT01546038** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 255 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** PF-04449913
- **DRUG:** Low dose ARA-C (LDAC)
- **DRUG:** PF-04449913
- **DRUG:** Decitabine
- **DRUG:** PF-04449913
- **DRUG:** Daunorubicin
- **DRUG:** Cytarabine
- **DRUG:** PF-04449913
- **DRUG:** Daunorubicin
- **DRUG:** Cytarabine
- **DRUG:** PF-04449913
- **DRUG:** Low dose ARA-C (LDAC)

## Key facts

- **NCT ID:** NCT01546038
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-27
- **Primary completion:** 2017-01-03
- **Final completion:** 2019-03-04
- **Target enrollment:** 255 (ACTUAL)
- **Last updated:** 2020-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01546038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01546038, "A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01546038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*